within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01A_Tetracyclines.J01AA12_Tigecycline;

model Tigecycline
  extends Pharmacolibrary.Drugs.ATC.J.J01AA12;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>J01AA12</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Tigecycline is a glycylcycline antibiotic structurally related to tetracyclines. It is used to treat complicated skin and skin structure infections, complicated intra-abdominal infections, and community-acquired bacterial pneumonia caused by susceptible organisms. It is approved for clinical use in many countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters after intravenous administration in healthy adult volunteers.</p><h4>References</h4><ol><li><p>Frampton, JE, &amp; Curran, MP (2005). Tigecycline. <i>Drugs</i> 65(18) 2623–2637. DOI:<a href=&quot;https://doi.org/10.2165/00003495-200565180-00008&quot;>10.2165/00003495-200565180-00008</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16392879/&quot;>https://pubmed.ncbi.nlm.nih.gov/16392879</a></p></li><li><p>Korth-Bradley, JM, et al., &amp; Morgan, MY (2011). Pharmacokinetics and safety of a single intravenous dose of the antibiotic tigecycline in patients with cirrhosis. <i>Journal of clinical pharmacology</i> 51(1) 93–101. DOI:<a href=&quot;https://doi.org/10.1177/0091270010363477&quot;>10.1177/0091270010363477</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20308689/&quot;>https://pubmed.ncbi.nlm.nih.gov/20308689</a></p></li><li><p>Rello, J (2005). Pharmacokinetics, pharmacodynamics, safety and tolerability of tigecycline. <i>Journal of chemotherapy (Florence, Italy)</i> 17 Suppl 1 12–22. DOI:<a href=&quot;https://doi.org/10.1179/joc.2005.17.Supplement-1.12&quot;>10.1179/joc.2005.17.Supplement-1.12</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16285354/&quot;>https://pubmed.ncbi.nlm.nih.gov/16285354</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Tigecycline;
